These innovative compounds represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://lilliyoos502816.wizzardsblog.com/39112388/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide